全文获取类型
收费全文 | 163789篇 |
免费 | 7432篇 |
国内免费 | 1355篇 |
专业分类
耳鼻咽喉 | 2057篇 |
儿科学 | 7446篇 |
妇产科学 | 3241篇 |
基础医学 | 15526篇 |
口腔科学 | 5926篇 |
临床医学 | 11157篇 |
内科学 | 35041篇 |
皮肤病学 | 3590篇 |
神经病学 | 11397篇 |
特种医学 | 6347篇 |
外国民族医学 | 2篇 |
外科学 | 32709篇 |
综合类 | 5995篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 11751篇 |
眼科学 | 2624篇 |
药学 | 10515篇 |
31篇 | |
中国医学 | 3147篇 |
肿瘤学 | 4072篇 |
出版年
2023年 | 3964篇 |
2022年 | 5107篇 |
2021年 | 7520篇 |
2020年 | 5469篇 |
2019年 | 15106篇 |
2018年 | 12162篇 |
2017年 | 7062篇 |
2016年 | 2467篇 |
2015年 | 3072篇 |
2014年 | 4751篇 |
2013年 | 3565篇 |
2012年 | 2997篇 |
2011年 | 7163篇 |
2010年 | 3687篇 |
2009年 | 3375篇 |
2008年 | 3166篇 |
2007年 | 2542篇 |
2006年 | 2127篇 |
2005年 | 2380篇 |
2004年 | 2300篇 |
2003年 | 1774篇 |
2002年 | 2185篇 |
2001年 | 2443篇 |
2000年 | 3377篇 |
1999年 | 3649篇 |
1998年 | 3368篇 |
1997年 | 2351篇 |
1996年 | 1628篇 |
1995年 | 1153篇 |
1994年 | 1204篇 |
1993年 | 835篇 |
1992年 | 876篇 |
1991年 | 721篇 |
1990年 | 729篇 |
1989年 | 524篇 |
1988年 | 555篇 |
1987年 | 368篇 |
1985年 | 4327篇 |
1984年 | 6106篇 |
1983年 | 4553篇 |
1982年 | 4678篇 |
1981年 | 4274篇 |
1980年 | 3782篇 |
1979年 | 3406篇 |
1978年 | 2924篇 |
1977年 | 2190篇 |
1976年 | 2466篇 |
1975年 | 2071篇 |
1974年 | 1774篇 |
1973年 | 1692篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
72.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
73.
74.
目的 探讨电针复合靶控输注(Target Controlled Infusion, TCI)在单肺通气食管癌开胸手术麻醉中的应用价值。方法 选取于我院拟行单肺通气食管癌开胸切除手术患者60例作为研究对象。随机将其分为试验组与对照组,对照组30例采取气管插管全麻及TCI靶控输注维持麻醉深度,试验组30例则在对照组方案基础上辅助电针麻醉,记录两组患者手术麻醉时间、药物用量、苏醒时间、并发症;以及术前(TⅠ)、插管前即刻(TⅡ)、插管后1 min(TⅢ)、切皮即刻(TⅣ)、去骨时(TⅤ)、拔管即刻(TⅥ)时平均动脉压(MAP)、平均心率(HR)、BIS值;术前、术后1天、术后3天简易智能精神状态检查量表(MMSE);并于麻醉诱导前(T0)、手术开始2 h(T1)、术后1天(T2)、术后3天(T3)时抽取患者外周静脉血检测IL-1β、IL-6、IL-10、TNF-α浓度。结果 试验组手术用时、麻醉时间略低于对照组,但差异无统计学意义(P>0.05),试验组异丙酚、舒芬太尼用量以及苏醒时间均明显低于对照组(P<0.05);TⅡ时两组平均动脉压(Mean Arterial Pressure, MAP)、心率(Heartrate, HR)较术前明显降低,且试验组MAP明显低于对照组(P<0.05),但两组TⅡ时HR比较无显著差异(P>0.05);TⅢ、TⅥ时对照组MAP、HR明显高于TⅠ时,而试验组MAP、HR与TⅠ比较无显著差异(P>0.05)。术后1天、3天试验组简易智能精神状态检查量表(Mini-Mental State Examination, MMSE)评分低于对照组,有显著性差异(P<0.05)。T1、T2、T3时试验组白介素-1β(IL-1β)、白介素-6(IL-6)、肿瘤坏死因子(Tumor Necrosis Factor-α, TNF-α)水平明显低于对照组(P<0.05),白介素-10(IL-10)水平明显高于对照组(P<0.05)。结论 采用电针复合TCI靶控输注麻醉方案可有效提升单肺通气食管癌开胸手术麻醉效果,能够降低患者术后认知功能障碍发生风险。 相似文献
75.
《Journal of Cardiovascular Computed Tomography》2019,13(5):254-260
Invasive coronary plaque imaging such as intravascular ultrasound and optical coherence tomography has been widely used to observe culprit or non-culprit coronary atherosclerosis, as well as optimize stent sizing, apposition and deployment. Coronary computed tomographic angiography (CTA) is non-invasively available to assess coronary artery disease (CAD) and has become an appropriate strategy to evaluate patients with suspected CAD. Given recent technologies, semi-automated plaque software is available to identify coronary plaque stenosis, volume and characteristics and potentially allows to be used for the assessment of more details of plaque information, progression and future risk as a surrogate tool of the invasive imaging modalities. This review article aims to focus on various evidence in coronary plaque imaging by coronary CTA and describes how accurate coronary CTA can classify coronary atherosclerosis. 相似文献
76.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献77.
78.
79.
80.